Nonalcoholic fatty liver disease (NAFLD) is caused by a buildup of fat in the liver. A proportion of NAFLD sufferers will also experience injury to their hepatocytes, which can lead to nonalcoholic…
Immunotherapy is one of the most exciting areas of oncology drug development. Numerous manufacturers and investors are entering the field and are rapidly expanding and diversifying their portfolios…
The availability of novel disease-modifying therapies (DMTs)—Copaxone 40 mg three times weekly (3TW), Plegridy, Lemtrada, oral DMTs—has complicated clinical decision-making and treatment choice…
Last Updated 15 October 2015 The type 2 diabetes therapy market will rapidly expand over our 2014-2024 study period, fueled by the disease’s increasing prevalence and a high unmet need for drugs…
This report examines the management of acute kidney injury (AKI) patients from the perspective of nephrologists and critical care physicians in the US. Emphasis is on self-reported patient load,…
LaunchTrends: Ibrance (Wave 2) is the second in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched breast cancer…
Driven by changing demographics and increasing medical costs, both mature and emerging markets are adopting novel strategies to manage their domestic healthcare systems. A range of methods are…
Outpatient parenteral antimicrobial therapy (OPAT) allows patients with clinically stable infections (e.g., skin and soft tissue infections, bone and joint infections, osteomyelitis, intra-…
How Will Physician and Payer Attitudes and Decisions Shape this Market? The treatment of metastatic colorectal cancer (mCRC) is increasingly driven by patients’ RAS mutational status of their…
A sudden, mechanical head injury that disrupts brain function is termed traumatic brain injury (TBI). Motor vehicle accidents, violence, and falls are the most common causes of TBI. Symptoms such…
How Does Cost versus Dosing Impact Prescriber Preferences and Payer Policy? The prevalence of age-related macular degeneration (AMD) is increasing with the aging population in China. Therapies…
Last Updated 28 September 2015 The market for Alzheimer’s disease (AD) pharmacotherapies offers enormous commercial opportunity driven by considerable unmet need and looming societal burden. The…
How Are Payer Strategies and Prescriber Preferences Shaping the Non-Insulin Treatment Algorithm? Although a high opportunity market, the therapeutic space for type 2 diabetes (T2D) is set to…
Gastric and gastroesophageal junction (GEJ) adenocarcinoma is characterized by poor prognosis. Japan has the highest incidence of gastric and GEJ adenocarcinoma among the markets under study,…
Gram-negative pathogens (GNPs) are clinically important pathogens in both the hospital and outpatient settings. GNPs are often acquired in healthcare facilities, and therefore have a high incidence…